OS THERAPIES INCORPORATED Depreciation
OS THERAPIES INCORPORATED (OSTX) reported Depreciation of $695 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2025-05-15
- OS THERAPIES INCORPORATED depreciation for the quarter ending 2025-03-31 was $695.00, a 0.00% change year-over-year.
- OS THERAPIES INCORPORATED depreciation for the quarter ending 2024-12-31 was $1.39K.
- OS THERAPIES INCORPORATED depreciation for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- OS THERAPIES INCORPORATED depreciation for the quarter ending 2024-06-30 was $695.00, a 13.66% decline year-over-year.
- OS THERAPIES INCORPORATED depreciation for fiscal 2024 was $2.78K, a 34.12% decline from fiscal 2023.
- OS THERAPIES INCORPORATED depreciation for fiscal 2023 was $4.22K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-03-31 | $695.00 10-Q · filed 2025-05-15 | $2.08K derived: sum of 2 quarters · filed 2025-05-15 | $2.08K derived: sum of 3 quarters · filed 2025-05-15 | $2.78K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $1.39K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.39K derived: sum of 2 quarters · filed 2025-03-31 | $2.08K derived: sum of 3 quarters · filed 2025-03-31 | $2.78K 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $695.00 derived: sum of 2 quarters · filed 2024-11-15 | $1.39K 10-Q · filed 2024-11-15 | $1.39K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | $695.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.39K 10-Q · filed 2024-08-14 | $1.39K derived: sum of 3 quarters · filed 2025-05-15 | $4.71K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | $695.00 10-Q · filed 2025-05-15 | $695.00 derived: sum of 2 quarters · filed 2025-05-15 | $4.01K derived: sum of 3 quarters · filed 2025-05-15 | $4.82K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.31K derived: sum of 2 quarters · filed 2025-03-31 | $4.12K derived: sum of 3 quarters · filed 2025-03-31 | $4.22K 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $4.12K derived: sum of 2 quarters · filed 2024-11-15 | $4.22K 10-Q · filed 2024-11-15 | |
| 2023-06-30 | $805.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $905.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $100.00 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |